Abbott Japan

What Abbott Japan does

Abbott Japan is the Japanese operating arm of Abbott Laboratories (NYSE: ABT), the 1888-founded U.S. healthcare major. In Japan the business is carried through three registered entities — Abbott Japan合同会社 (overall), Abbott Medical Japan合同会社 (formed April 2020 by combining the cardiac and neuromodulation units), and Abbott Diagnostics Medical株式会社 — with offices concentrated in Tokyo's Minato-ku (Shiodome) and Chuo-ku (Tsukiji), and 1,001-5,000 employees covering direct sales, training, and customer demonstration functions.

The portfolio spans four segments: medical devices (FreeStyle Libre continuous glucose monitoring; cardiovascular rhythm-management and structural-heart systems including AVEIR leadless pacemaker, XIENCE drug-eluting stents, Navitor TAVI, MitraClip, and TriClip tricuspid repair; neuromodulation devices such as Liberta RC DBS and Eterna SCS paired with NeuroSphere Virtual Clinic remote programming), diagnostics (Alinity-series clinical chemistry/immunoassay/hematology systems, GLP systems Track laboratory automation, and rapid/point-of-care tests), nutrition (Ensure adult supplements and the Glucerna line including the new low-carb Glucerna REX 1.5), and established pharmaceuticals. Recently launched and newly approved products in 2024-2026 include TriClip (Japan's first percutaneous tricuspid repair system), Amulet LAA occluder, AVEIR DR leadless pacemaker, Liberta RC DBS, Eterna SCS, and CANCERGARD multi-cancer early detection via the March 2026 Exact Sciences acquisition.

Abbott Japan monetizes through direct enterprise sales to hospitals and cardiology/neurology departments, dedicated field sales forces by division, and — for consumer nutrition — retail pharmacy and e-commerce channels. Pricing is largely governed by Japan's national health insurance reimbursement categories. The company extends its reach via co-promotion with Suzuke Group for diabetes care, partnerships with QST (neurodegenerative biomarkers), Medtronic (CGM-insulin pump integration), and the Swiss/NN Running Team (Eliud Kipchoge), and uses the Abbott World Marathon Majors sponsorship plus a HeartMates patient community as flagship brand and community-engagement channels.

Name

Abbott Japan

Legal name

アボットジャパン合同会社

Website

https://abbott.co.jp

Company type

Public

Founded year

1888

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Abbott Japan is the Japanese subsidiary of Abbott Laboratories, selling medical devices (FreeStyle Libre CGM, cardiovascular implants such as TriClip and AVEIR, neuromodulation systems), diagnostics (Alinity analyzers, GLP systems Track), and nutrition products (Ensure, Glucerna) to hospitals, clinicians, and consumers across Japan.

Ownership category

akta.pro rank

Product category

Medical Devices

NAICS

Surgical and Medical Instrument Manufacturing (339112), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Pharmaceutical Preparation Manufacturing (325412)

SIC

Surgical & Medical Instruments & Apparatus (3841), Electromedical & Electrotherapeutic Apparatus (3845), Pharmaceutical Preparations (2834)

akta.pro primary industry

Cardiometabolic RPM & Chronic Disease Management (diabetes, hypertension, CHF, obesity) (HLALAFAA)

akta.pro secondary industries

Blood Glucose Monitoring Devices (Consumer CGM & Smart Glucometers) (CRACAQAE), Medical Nutrition & Meal Replacement (RTD, Bars, Powders) (CRADAGAN), Personal Medical Devices & Home Diagnostics (Thermometers, Blood Pressure Monitors, Glucose Meters, Rapid Tests) (CRADAMAK)

Keywords

• Continuous glucose monitoring
• Cardiovascular medical devices
• Diagnostic immunoassays
• Neuromodulation therapy
• Clinical nutrition products

Headquarters

HQ city

Tokyo

HQ country

Japan

HQ region

Asia

Offices4 records

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Supply Chain, Marketing or Sales, Operations, Infrastructure

Revenue model

1. Medical Devices: Cardiac rhythm management, electrophysiology, structural heart, heart failure, and diabetes care devices including implants (pacemakers, stents, clips), ablation catheters, neuromodulation systems, and CGM sensors. Revenue from both initial device sales and recurring sensor/supply revenue.
2. Diagnostics: Core lab diagnostics, rapid diagnostics, gene testing, and point-of-care testing products including instruments, reagents, and consumables sold to hospitals and laboratories.
3. Nutrition Products: Adult and pediatric nutritional products sold through retail pharmacies, hospitals, and e-commerce channels. Includes Ensure, Glucerna, PediaSure, and Enteral nutrition products.
4. Established Pharmaceuticals: Brand generic pharmaceuticals sold primarily in emerging markets across Latin America, Asia Pacific, and Middle East.
5. Cancer Diagnostics (Exact Sciences): CANCERGARD multi-cancer early detection test and COLOGUARD colorectal cancer screening test following the 2026 acquisition of Exact Sciences.

Pricing tiers

Go-to-market motion3 records

Distribution channels5 records

Marketing channels9 records

Core offering

Abbott Japan manufactures, develops, and distributes medical devices, in-vitro diagnostics, and nutritional products in Japan. Its portfolio spans the FreeStyle Libre continuous glucose monitoring system, structural heart and cardiac rhythm devices (TriClip, MitraClip, Navitor, Tendyne, Amulet, Aveir, Volt PFA, TactiFlex Duo, XIENCE), neuromodulation systems (Liberta RC DBS, Eterna SCS), diagnostic platforms (Alinity series, GLP systems Track), and adult/pediatric nutritional products (Ensure, Glucerna) plus screening tests (CANCERGUARD, COLOGUARD). The business serves healthcare professionals, hospitals, clinical laboratories, and individual patients and families in Japan.

Product overview

Abbott Japan offers a diversified healthcare portfolio spanning four main business areas: Diagnostics (Alinity laboratory systems, rapid tests, point-of-care testing), Medical Devices (FreeStyle Libre CGM, TriClip/MitraClip valve repair, pacemakers, neuromodulation systems like Liberta DBS and Eterna SCS, ablation systems), Nutrition (Glucerna and Ensure enteral nutrition products), and Established Pharmaceuticals. The medical device portfolio includes cardiovascular products (rhythm management, structural heart, heart failure), diabetes care (FreeStyle Libre CGM systems), and neuromodulation (DBS, SCS). Recent strategic expansion includes cancer diagnostics through the acquisition of Exact Sciences and its CANCERGUARD multi-cancer early detection test. The company serves both healthcare professionals and patients, with products ranging from hospital-based diagnostic equipment to consumer wellness devices.

Differentiator

Problem solved

Functional benefit

Brands

• Abbott World Marathon Majors (アボット・ワールドマラソンメジャーズ): Title sponsorship of the World Marathon Majors series including Tokyo, Boston, London, Berlin, Chicago, New York, and Sydney marathons.
• FreeStyleリブレ (FreeStyle Libre)
• MitraClip
• TriClip
• XIENCE
• Navitor
• エンシュア (Ensure)
• グルセルナ (Glucerna)
• NeuroSphere (ニューロスフィア)
• HeartMates (ハートメイツ)
• Women in STEM Network

Products and services

• FreeStyle Libre 3 Continuous Glucose Monitoring System

Quantifiable outcome

• FreeStyle Libre CGM users showed HbA1c decrease of 0.6% and spent 2.5 hours more per day in normal glucose range vs finger-prick users in FreeDM2 randomized trial.
• +6 more outcomes

Named customers9 records

Segments6 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature10 records

Partnerships

Eleven partnerships are on record, tiered flagship, minor and major.

• Exact Sciences CorporationflagshipStrategic or Co-development Partner · 23 March 2026Abbott completed the acquisition of Exact Sciences on March 23, 2026, establishing leadership in the growing cancer screening and diagnostics market. Exact Sciences brings CANCERGARD (multi-cancer early detection) and COLOGUARD (colorectal cancer screening) to Abbott's portfolio.
• AtaCor MedicalminorStrategic or Co-development Partner · 1 January 2026Abbott partnered with AtaCor Medical in January 2026 to develop next-generation extravascular implantable cardioverter-defibrillator (EV-ICD) systems for patients with life-threatening arrhythmias.
• Big Ten Conference (US College Sports League)minorGTM or Marketing Partner · 1 March 2025Abbott partnered with the Big Ten Conference in the US in March 2025 to conduct a nationwide blood donation contest aimed at increasing US blood supply.
• HeartMates Patient CommunityflagshipStrategic or Co-development Partner · 1 January 2025HeartMates is Abbott's patient community connecting cardiovascular disease patients, families, and healthcare providers. Features ambassador Damar Hamlin (NFL player who survived cardiac arrest). The program supports patients overcoming cardiac events to participate in marathons and share mutual support experiences.
• Medtronic (CGM-Insulin Pump Integration)majorTechnology or Integration · 1 August 2024Abbott announced a global partnership with Medtronic in August 2024 to integrate Abbott's FreeStyle Libre CGM with Medtronic's insulin pumps, enabling automated insulin delivery for diabetes patients.
• National Institutes for Quantum and Radiological Science and Technology (QST)majorStrategic or Co-development Partner · 20 February 2024Abbott and QST agreed in February 2024 to accelerate joint development of blood diagnostic biomarkers capable of measuring neurodegenerative diseases such as dementia. This strategic R&D collaboration leverages Abbott's diagnostic technology capabilities with QST's quantum science expertise.
• Suzuke Group (スズケングループ)majorChannel Partner/ Reseller/ Distributor · 23 January 2024Abbott entered a co-promotion agreement with Suzuke Group (January 2024) aimed at advancing diabetes care development in Japan. Suzuke Group distributes and promotes Abbott's diabetes care products through its extensive healthcare distribution network in Japan.
• Novartis Pharma (ノバルティス ファーマ)minorGTM or Marketing Partner · 1 January 2024Abbott Medical Japan and Novartis Pharma co-promote cardiovascular disease information activities targeting healthcare professionals. Shared use of physician contact information for collaborative cardiovascular education programs.
• Japanese Red Cross and J-PRISMminorGTM or Marketing Partner · 19 July 2023Abbott participates in J-PRISM (Japan blood donation awareness initiatives) and collaborates with Japanese Red Cross on blood donation promotion activities through employee volunteer groups.
• NN Running Team (Eliud Kipchoge)flagshipStrategic or Co-development Partner · 1 January 2021Abbott partnered with Eliud Kipchoge and his NN Running Team starting in 2021. Kipchoge won the 2022 Tokyo Marathon with a course record and returned for the 2024 Tokyo Marathon. He serves as a brand ambassador promoting the connection between running, health, and human potential.
• Abbott World Marathon MajorsflagshipStrategic or Co-development Partner · 1 January 2015Abbott has been title sponsor of the Abbott World Marathon Majors (Tokyo, Boston, London, Berlin, Chicago, New York) since 2015. The partnership supports diverse runners overcoming health challenges, promotes the 'Life to the Fullest' purpose, and generates significant brand visibility through the Six Star Finisher program and cheer zones at each marathon.

Scale indicators10 records

Recent moves9 records

Expansion highlights6 records

Direct peers

• Terumo: Japan-headquartered global medical device company with overlapping interventional cardiology, hospital products, and pharmaceutical solutions franchises. Comparable to Abbott as a diversified Japan-based medical device incumbent competing for the same hospital contracts.
• Dexcom: Direct CGM competitor to Abbott's FreeStyle Libre franchise with the G7 system. Competes for the same Japanese diabetes patients, providers, and NHI reimbursement categories, and is the most direct threat to Abbott's CGM market leadership.
• Medtronic: Global medical device leader with directly overlapping cardiovascular (pacemakers, structural heart, cardiac ablation), neuromodulation, and diabetes care franchises. Abbott and Medtronic are CGM-pump integration partners in Japan and globally, competing in multiple device categories.
• Edwards Lifesciences: Direct competitor in transcatheter structural heart with the SAPIEN TAVI platform, competing head-to-head with Abbott's Navitor TAVI system in Japan. Both companies are pursuing tricuspid and mitral interventions.
• Boston Scientific: Direct competitor in cardiovascular devices including structural heart, cardiac rhythm management, and peripheral interventions. Targets the same Japanese cardiology hospital accounts as Abbott's MitraClip, TriClip, AVEIR, and XIENCE franchises.

Broad incumbents

• Siemens Healthineers: Broad incumbent in clinical laboratory diagnostics (Atellica, ADVIA Centaur) competing directly with Abbott's Alinity series and GLP systems Track automation. Also has a large installed base in Japanese hospital and reference laboratories.
• Roche Diagnostics: Broad incumbent in clinical diagnostics (cobas systems) and diabetes care (Accu-Chek), directly competing with Abbott's Alinity and FreeStyle Libre portfolios. Operates at greater scale and breadth but with overlapping core lab and glucose monitoring offerings.
• Nestlé Health Science: Broad incumbent in medical and clinical nutrition (Peptamen, Impact, Isosource) competing with Abbott's Ensure and Glucerna enteral nutrition lines in Japan. Comparable as a global nutrition-health platform selling into hospitals, retail, and home-care channels.
• Danone Nutricia: Broad incumbent in medical nutrition (Nutrison, Fortisip) and infant/elderly nutrition competing with Abbott's Ensure and Glucerna in Japan. Comparable product portfolio, channel mix, and target patient populations.

Regional players

• Olympus: Japan-headquartered medical device leader with significant overlap in hospital-channel medical devices, although focused on endoscopy rather than Abbott's cardiovascular and diabetes franchises. Comparable as a major Japan-domestic medical device peer competing for the same hospital capital equipment budgets.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat7 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/AbbottNews
• YouTubeyoutube.com/c/abbott
• Facebookfacebook.com/Abbott
• LinkedInlinkedin.com/company/abbott-
• Instagraminstagram.com/abbottglobal

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Subsidiaries5 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Abbott Japan